<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lupfer, Christopher</style></author><author><style face="normal" font="default" size="100%">Besnouin, Didier</style></author><author><style face="normal" font="default" size="100%">Tepper, Samuel E</style></author><author><style face="normal" font="default" size="100%">Maselko, Maciej</style></author><author><style face="normal" font="default" size="100%">Patton, Kristin M</style></author><author><style face="normal" font="default" size="100%">Pastey, Manoj</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Increased Survivorship and Altered Cytokine Profile from Treatment of Influenza A H1N1-Infected Mice with Ekybion: A Drug Complex of Natural Extracts and Inorganic Compounds.</style></title><secondary-title><style face="normal" font="default" size="100%">Evidence-based complementary and alternative medicine : eCAM</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Evid Based Complement Alternat Med</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">2011</style></volume><pages><style face="normal" font="default" size="100%">192079</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Ekybion is a drug complex of 16 natural extracts and inorganic compounds designed to treat a variety of respiratory pathogens of bacterial and viral origin. It is licensed throughout Europe for the treatment of respiratory tract infections from equine parainfluenza type 3 and equine herpes virus type 1 in equine stables. The purpose of this paper was to test the efficacy of Ekybion on a well-developed animal model of influenza A infection and determine a mode of action. Experiments were performed with Balb/c mice infected with a lethal dose of influenza A/PR/8/34 H1N1 virus and treated with nebulized Ekybion every 8 h in a time-dependant or dose-dependant fashion. These experiments showed that mice treated prior to infection with Ekybion had a higher survival rates (~46%) compared with untreated animals (~0%). Paradoxically, these mice showed no significant difference in lung virus titer or weight loss. There was, however, a decrease in the level of GM-CSF, IL-6, and G-CSF cytokines in the lungs of Ekybion-treated, infected mice. It is possible that decreases in proinflammatory cytokines may have contributed to increased survivorship in Ekybion-treated influenza-infected mice.</style></abstract><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/20981272?dopt=Abstract</style></custom1></record></records></xml>